Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AT-101 + Bicalutamide |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AT-101 | R-(-)-gossypol acetic acid|AT101 | BCL2 Family Inhibitor 6 | AT-101 is a pan-BCL2 inhibitor that inhibits the anti-apoptotic proteins BCL2, BCL-XL, and MCL1, potentially resulting in increased tumor cell apoptosis and decreased cell proliferation (PMID: 26089640, PMID: 16611409, PMID: 31388792). | |
| Bicalutamide | Casodex | Hormone - Anti-androgens 57 | Casodex (bicalutamide) is an androgen-receptor antagonist that binds androgen receptors and inhibits androgen binding, therefore inhibits AR-dependent growth of tumor cells (PMID: 9428389). Casodex (bicalutamide) is approved, in combination with a luteinizing hormone-releasing hormone (LHRH) analog, for metastatic carcinoma of the prostate (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|